- Home
- LITS vs RCEL Comparison
LITS vs RCEL Comparison
Compare LITS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITS
- RCEL
- Stock Information
- Founded
- LITS N/A
- RCEL N/A
- Country
- LITS United States
- RCEL United States
- Employees
- LITS N/A
- RCEL N/A
- Industry
- LITS Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- LITS Health Care
- RCEL Health Care
- Exchange
- LITS Nasdaq
- RCEL Nasdaq
- Market Cap
- LITS 96.2M
- RCEL 113.7M
- IPO Year
- LITS 2003
- RCEL N/A
- Fundamental
- Price
- LITS N/A
- RCEL $4.56
- Analyst Decision
- LITS
- RCEL Strong Buy
- Analyst Count
- LITS 0
- RCEL 4
- Target Price
- LITS N/A
- RCEL $13.75
- AVG Volume (30 Days)
- LITS N/A
- RCEL 286.8K
- Earning Date
- LITS N/A
- RCEL 11-06-2025
- Dividend Yield
- LITS N/A
- RCEL N/A
- EPS Growth
- LITS N/A
- RCEL N/A
- EPS
- LITS N/A
- RCEL N/A
- Revenue
- LITS N/A
- RCEL $74,884,000.00
- Revenue This Year
- LITS N/A
- RCEL $28.23
- Revenue Next Year
- LITS N/A
- RCEL $35.24
- P/E Ratio
- LITS N/A
- RCEL N/A
- Revenue Growth
- LITS N/A
- RCEL 38.32
- 52 Week Low
- LITS N/A
- RCEL $3.60
- 52 Week High
- LITS N/A
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- LITS N/A
- RCEL 46.58
- Support Level
- LITS N/A
- RCEL $4.12
- Resistance Level
- LITS N/A
- RCEL $4.44
- Average True Range (ATR)
- LITS 0.00
- RCEL 0.25
- MACD
- LITS 0.00
- RCEL 0.03
- Stochastic Oscillator
- LITS 0.00
- RCEL 50.00
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.